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Abstract
Patients with chronic kidney disease (CKD) are affected by mineral and bone disorder (MBD), resulting in abnormalities in
serum calcium (Ca), phosphorous (P) and parathyroid hormone (PTH). Changes in mineral metabolism have also been
associated with higher rates of both all-cause and cardiovascular-related mortality. The majority of haemodialysis patients
are also deficient in the endogenous hormone 1,25-dihydroxyvitamin D (calcitriol), often contributing to increased
secondary hyperparathyroidism (SHPT) and consequently to abnormal levels of Ca, P and PTH. Thus P overload and SHPT
are well-known targets of medical treatments, such as P binders, vitamin D and calcimimetics, although with still limited
evidence-based advantages in terms of survival. The tough hedge that is still keeping nephrologists far from a conclusive
and winning approach against CKD-MBD is reasonably related to the still partial comprehension of the molecular pathways
involved in a complex, multifactorial and extreme process.
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Despite therapeutic advances, mortality rates remain high among
patients with chronic kidney disease (CKD), particularly those
undergoing haemodialysis (HD) [1]. The main cause of mortality in
these patients is attributed to cardiovascular-related diseases [1].
However, patients with CKD are also affected by mineral and bone
disorder (MBD), resulting in abnormalities in serum calcium (Ca),
phosphorous (P) and parathyroid hormone (PTH) [2]. Changes in
mineral metabolism have also been associated with higher rates
of both all-cause and cardiovascular-relatedmortality [3–6].
In 2003, the US National Kidney Foundation implemented
the Kidney Disease Outcomes Quality Initiative (KDOQI) inter-
national guidelines to establish target levels for serum PTH, Ca
and P in an effort to help lower secondary hyperparathyroidism
(SHPT)-related mortality [7]. Unfortunately, evidence suggests
that these restrictive guidelines are difficult to achieve, espe-
cially over the long term [8]. Since these guidelines were imple-
mented, there has been an increased awareness of SHPT in
addition to the introduction of newer treatment options in clini-
cal practice. Furthermore, clinical guidelines are available for
optimal levels of serummarkers of CKD-MBD, but target param-
eters are not achieved in many HD patients [9].
The 2009 Kidney Disease: Improving Global Outcomes
(KDIGO) Clinical Practice Guideline on the Management of CKD-
MBD was intended to assist clinicians in treating patients with
CKD Stages 3–5 who are also on dialysis [10]. Very recently (July
2017), updated KDIGO guidelines confirm those targets for CKD-
MBD biomarkers [11].
Although several studies have examined the association
between mineral levels and the impact of achievement of CKD-
MBD target ranges on mortality rates in HD patients [12, 13], only
a few studies have been conducted to date on incident HD
patients [14–16]. Furthermore, evidence indicates that in incident
HD patients, mortality rates are higher in the early stages (first
3–4months) of dialysis, warranting studies in this setting [16].
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In the present issue of Clinical Kidney Journal, Fouque et al.
present data from the Photo-Graphe3 study in France [17]. This
is a prospective, multicentre, observational study in 9010 inci-
dent HD patients followed for 32months. Interestingly, authors
observed that the proportion achieving the three KDIGO targets
increased from 11% to 16% (P< 0.0001) over 24months, remain-
ing stable afterwards, with significant improvement in serum P
and serum Ca levels, without any significant improvement in
serum PTH levels [17].
Other studies were performed to investigate similar issues.
In Italy, we performed the FARO-2 study. The aim of the FARO-2
study was to assess SHPT management and alignment with
CKD-MBD guideline target ranges [15, 16] on mortality rates in a
subgroup of incident HD patients from the FARO study [6, 12,
18]. In the FARO-2 study, we showed that mortality rates at
24months are associated with a reduction by as much as 25% in
patients who achieved target ranges for three of the bone and
mineral parameters (Ca, P and PTH) according to KDOQI guide-
lines. Moreover, by attaining target ranges for the three parame-
ters at least once over the survey, survival rates were still 20%
greater than those never achieving the KDOQI targets. The find-
ings from our survival analysis supported these previous stud-
ies and, more importantly, extend our knowledge by
demonstrating that the achievement of KDOQI targets over
time were associated with a significant improvement in sur-
vival. Furthermore, we performed a retrospective analysis to
determine how patients fared in terms of achievement of target
ranges according to the newer KDIGO guidelines [10, 11]. It is
important to underline that while the target ranges for Stage 5
CKD HD patients for intact PTH concentrations are 150–300pg/
mL according to KDOQI guidelines [7], the newer KDIGO guide-
lines recommend maintaining PTH levels 2- to 9-fold the upper
normal limit [10, 11], corresponding to a range of 130–600pg/mL
[18].
In the FARO-2 study, as we had expected, the number of
patients on target was increased by following the KDIGO guide-
lines. While only 35.9% of patients were on target for PTH levels
according to the KDOQI guidelines, this proportion increased to
63% when the KDIGO guidelines were adopted. Likewise, the
proportion of patients with three biochemical parameters on
target (tri-target) at least once was higher for the KDIGO (46%)
compared with the KDOQI guidelines (30.1%) and in patients
who attained tri-target for all six visits (25.8% for KDIGO versus
13.3% for KDOQI). Since the KDIGO guidelines are less restric-
tive, a greater proportion of patients will likely have more
severe hyperparathyroidism. Therefore it was not surprising
that our analysis also revealed a higher mortality rate in those
patients who were never on target according to KDIGO ranges
(46%) compared with KDOQI ranges (29.7%).
Going back to the French cohort, a prospective observational
study was performed on 8377 prevalent patients receiving inter-
mittent HD therapy that examined the association between
mortality and serum concentrations of phosphate, Ca and PTH
through KDIGO target ranges [19]. The authors described a ‘grey
zone’ where the precise biochemical targets are difficult to
define, with the exception of avoiding extreme values. The
KDIGO guidelines did not recommend precise threshold values,
but rather ‘normal’ laboratory values, which may differ from
one PTH kit to another. This study also confirmed the relative
risk of low intact PTH values, as proposed by the KDIGO recom-
mendations [19].
Table 1 presents a summary of the present study [17] and
the FARO-2 study [16] in incident HD patients.
One of the difficulties in achieving multiple CKD-MBD tar-
gets consistently is that the majority of treatment approaches
reflect a compromise between controlling PTH and controlling
Ca and P [20]. Although newer therapies, such as combined cal-
cimimetic and active vitamin D therapy, have been shown to
enhance the ability of patients to reach CKD-MBD target values
for biochemical parameters [21], their long-term safety and
efficacy, and ultimately mortality rates, still need to be verified
in randomized controlled trials. Long-term randomized con-
trolled trials are still needed to determine the extent that these
therapies, administered in combination or as monotherapy,
provide a survival benefit.
In conclusion, considering the limitations of this
observational design, the benefit of achieving KDOQI targets
and the more recent KDIGO targets on survival in incident HD
patients remains to be confirmed in long-term prospective
randomized clinical trials.
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